Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System.

Fletcher EAK, van Maren W, Cordfunke R, Dinkelaar J, Codee JDC, van der Marel G, Melief CJM, Ossendorp F, Drijfhout JW, Mangsbo SM.

J Immunol. 2018 Jul 1;201(1):87-97. doi: 10.4049/jimmunol.1700911. Epub 2018 May 11.

PMID:
29752315
2.

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW.

Mol Immunol. 2018 Jan;93:115-124. doi: 10.1016/j.molimm.2017.11.004. Epub 2017 Nov 22.

PMID:
29175591
3.

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.

Irenaeus S, Schiza A, Mangsbo SM, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ.

Oncotarget. 2017 Jul 31;8(45):78573-78587. doi: 10.18632/oncotarget.19750. eCollection 2017 Oct 3.

4.

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.

Fletcher EAK, Eltahir M, Lindqvist F, Rieth J, Törnqvist G, Leja-Jarblad J, Mangsbo SM.

Int Immunopharmacol. 2018 Jan;54:1-11. doi: 10.1016/j.intimp.2017.10.021. Epub 2017 Oct 27.

5.

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.

Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich LC, Christiansson L, Karlsson H, Ullenhag G, Mangsbo SM, Dimberg A, Alemany R, Loskog A.

Gene Ther. 2017 Feb;24(2):92-103. doi: 10.1038/gt.2016.80. Epub 2016 Dec 1.

6.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM.

Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

7.

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.

Ellmark P, Mangsbo SM, Furebring C, Norlén P, Tötterman TH.

Cancer Immunol Immunother. 2017 Jan;66(1):1-7. doi: 10.1007/s00262-016-1909-3. Epub 2016 Oct 6. Review.

8.

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.

van Hooren L, Georganaki M, Huang H, Mangsbo SM, Dimberg A.

Oncotarget. 2016 Jul 1;7(31):50277-50289. doi: 10.18632/oncotarget.10364.

9.

Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells.

Vogel S, Grabski E, Buschjäger D, Klawonn F, Döring M, Wang J, Fletcher E, Bechmann I, Witte T, Durisin M, Schraven B, Mangsbo SM, Schönfeld K, Czeloth N, Kalinke U.

Sci Rep. 2015 Dec 16;5:18308. doi: 10.1038/srep18308.

10.

Kick-starting the cancer-immunity cycle by targeting CD40.

Ellmark P, Mangsbo SM, Furebring C, Tötterman TH, Norlén P.

Oncoimmunology. 2015 Mar 16;4(7):e1011484. eCollection 2015 Jul.

11.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM.

J Neuroimmunol. 2014 Dec 15;277(1-2):153-9. doi: 10.1016/j.jneuroim.2014.10.005. Epub 2014 Oct 18.

PMID:
25457841
12.

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P.

Clin Cancer Res. 2015 Mar 1;21(5):1115-26. doi: 10.1158/1078-0432.CCR-14-0913. Epub 2014 Oct 14.

13.

FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis.

Yilmaz-Elis AS, Ramirez JM, Asmawidjaja P, van der Kaa J, Mus AM, Brem MD, Claassens JW, Breukel C, Brouwers C, Mangsbo SM, Boross P, Lubberts E, Verbeek JS.

J Immunol. 2014 Jun 15;192(12):5540-7. doi: 10.4049/jimmunol.1303272. Epub 2014 May 19.

14.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

15.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

16.

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer.

Sandin LC, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27400.

17.

A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.

Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM.

J Immunother. 2014 Apr;37(3):155-62. doi: 10.1097/CJI.0000000000000028.

PMID:
24598450
18.

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.

Liljenfeldt L, Dieterich LC, Dimberg A, Mangsbo SM, Loskog AS.

Cancer Gene Ther. 2014 Mar;21(3):95-102. doi: 10.1038/cgt.2014.2. Epub 2014 Jan 31.

PMID:
24481488
19.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS.

Immunology. 2013 Oct;140(2):211-9. doi: 10.1111/imm.12129.

20.

FcγRIIb on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotoxic nephritis.

Sharp PE, Martin-Ramirez J, Mangsbo SM, Boross P, Pusey CD, Touw IP, Cook HT, Verbeek JS, Tarzi RM.

J Immunol. 2013 Jan 1;190(1):340-8. doi: 10.4049/jimmunol.1202250. Epub 2012 Nov 30.

21.

Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.

van Montfoort N, 't Hoen PA, Mangsbo SM, Camps MG, Boross P, Melief CJ, Ossendorp F, Verbeek JS.

J Immunol. 2012 Jul 1;189(1):92-101. doi: 10.4049/jimmunol.1103703. Epub 2012 May 30.

22.

Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo.

van Montfoort N, Mangsbo SM, Camps MG, van Maren WW, Verhaart IE, Waisman A, Drijfhout JW, Melief CJ, Verbeek JS, Ossendorp F.

Eur J Immunol. 2012 Mar;42(3):598-606. doi: 10.1002/eji.201141613. Erratum in: Eur J Immunol. 2012 Jun;42(6):1648.

23.

Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone.

Sharp PE, Martin-Ramirez J, Boross P, Mangsbo SM, Reynolds J, Moss J, Pusey CD, Cook HT, Tarzi RM, Verbeek JS.

Mol Immunol. 2012 Feb;50(1-2):49-56. doi: 10.1016/j.molimm.2011.12.007. Epub 2012 Jan 14.

PMID:
22244885
24.

Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.

Mangsbo SM.

BJU Int. 2011 Oct;108(7):1214-5. doi: 10.1111/j.1464-410X.2011.10499.x. No abstract available. Erratum in: BJU Int. 2011 Dec;108(11):1938. Mangsb, Sara [corrected to Mangsbo, Sara M].

25.

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH.

Clin Cancer Res. 2010 Jun 15;16(12):3279-87. doi: 10.1158/1078-0432.CCR-10-0385. Epub 2010 May 4.

26.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.

J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.

PMID:
20445343
27.

Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro.

Lund T, Mangsbo SM, Scholz H, Gjorstrup P, Tötterman TH, Korsgren O, Foss A.

Exp Clin Endocrinol Diabetes. 2010 Apr;118(4):237-44. doi: 10.1055/s-0029-1241825. Epub 2010 Jan 29.

PMID:
20119897
28.

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.

Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS, Nilsson B, Tötterman TH.

J Immunol. 2009 Nov 15;183(10):6724-32. doi: 10.4049/jimmunol.0902374. Epub 2009 Oct 28.

29.

Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages.

Eriksson F, Tsagozis P, Lundberg K, Parsa R, Mangsbo SM, Persson MA, Harris RA, Pisa P.

J Immunol. 2009 Mar 1;182(5):3105-11. doi: 10.4049/jimmunol.0800224.

30.

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.

Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH.

J Immunother. 2008 Jan;31(1):34-42.

PMID:
18157010

Supplemental Content

Loading ...
Support Center